Click here to join

Partnering & Collaborating

Accelerating the Future of


We are a globally active biotechnology company developing immunotherapeutic products for cancer and autoimmune diseases. Active collaborations are an integral part of our business and we have a number of collaborations underway with various corporations and academic institutions.


  • eftilagimod alpha (LAG-3Ig or IMP321) is being developed in conjunction with EOC Pharma who have licensed rights for China including Macau, Hong Kong and Taiwan. Immutep owns the rights to the rest of the world.
  • we have other collaborations with pharma, biotech and academia, e.g. LabCorp, MSD, Merck KGaA, Cytlimic, Monash University and University Hospital Pilsen.

Other Collaborations:

  • development of a LAG-3 depleting antibody (IMP731) in autoimmune diseases with GlaxoSmithKline;
  • development of a LAG-3 antagonist antibody (IMP701) for cancer immunotherapy with Novartis.

Collaboration and Licensing Opportunities

We welcome potential collaboration or licensing opportunities in oncology that would complement our existing portfolio and technology platform. We are also interested in novel therapeutic opportunities in other disease areas and with an immunotherapeutic background. 

If you are interested in a collaboration, licensing (in- and out-licensing) or partnership discussion we welcome you to contact us directly.

For information on partnerships, collaboration opportunities, and general licensing enquiries for Immutep, please email us at: